Mahmoud, Rami H. http://orcid.org/0000-0002-9322-7030
Mahmoud, Omar
Biazus Soares, Georgia
Yosipovitch, Gil
Article History
Received: 4 November 2023
Accepted: 17 March 2024
First Online: 13 April 2024
Declarations
:
: Rami H. Mahmoud, Omar Mahmoud, and Georgia Biazus Soares have nothing to disclose. Dr. Gil Yosipovitch serves as an advisory board member for Abbvie, Arcutis, BMS, Cara Therapuetics, GSK. Escient Health, Eli Lilly, Galderma, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals, Inc., Sanofi, TreviTherapeutics, and Vifor; Dr. Gil Yosipovitch receives grants/research funding from Eli Lilly, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Galderma, Escient, Sanofi Regeneron, and Celldex; Dr. Gil Yosipovitch Received Pathways grants as Investigator for Regeneron Pharmaceuticals, Inc. Sanofi. Gil Yosipovitch is an Editorial Board member of Dermtology and Therapy. Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.